Abstract
Computer Vision Syndrome is an emerging ocular condition resulting from prolonged and continuous exposure to screen. Despite its increasing prevalence in today’s digital league, the condition goes underdiagnosed as symptoms such as irritation of the eye, redness and dryness can be managed symptomatically, while the underlying light -induced ocular damage remains largely overlooked. Existing therapeutic options in Allopathy and Ayurveda provide temporary or non-specific relief, highlighting the need for a more specific approach. To address this gap, through this study a novel integrated approach merging Allopathic and Ayurvedic principles of healing. The formulation utilizes Triphala, recognized for its antioxidant, anti-inflammatory and rejuvenating properties, combined with sodium hyaluronate, an established ocular lubricant and a natural ocular component to specifically manage and treat computer vision syndrome. The dosage form was designed with an emphasis on enhanced therapeutic efficiency, improved patient compliance, ease of manufacturing and strong potential for large scale commercialization. Detailed physicochemical, stability and pharmacological evaluations confirmed the reliability of the formulation. In vitro permeation studies using Franz diffusion cells demonstrated efficient and favorable ocular penetration. Further histopathological findings carried out on goat corneal tissue, serving as a validated human corneal model, showed significant healing, regenerative and protective effects against light induced ocular damage. Overall, the findings strongly uphold the formulations potential as a targeted, novel and commercially viable therapy for computer vision syndrome.
Keywords: Cornea, Screen, Sodium hyaluronate, Triphala, Vitreo-retinal disease